173 related articles for article (PubMed ID: 29248965)
1. Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy.
Mehra N; Ganesan P; Ganesan TS; Veeriah S; Boopathy A; Radhakrishnan V; Dhanushkodi M; Rajaraman S; Ganesharajah S; Sagar TG
Med Oncol; 2017 Dec; 35(1):12. PubMed ID: 29248965
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
Navari RM; Gray SE; Kerr AC
J Support Oncol; 2011; 9(5):188-95. PubMed ID: 22024310
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
Navari RM; Einhorn LH; Passik SD; Loehrer PJ; Johnson C; Mayer ML; McClean J; Vinson J; Pletcher W
Support Care Cancer; 2005 Jul; 13(7):529-34. PubMed ID: 15700131
[TBL] [Abstract][Full Text] [Related]
4. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
Navari RM; Einhorn LH; Loehrer PJ; Passik SD; Vinson J; McClean J; Chowhan N; Hanna NH; Johnson CS
Support Care Cancer; 2007 Nov; 15(11):1285. PubMed ID: 17375339
[TBL] [Abstract][Full Text] [Related]
6. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Navari RM; Nagy CK; Gray SE
Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.
Trifilio S; Welles C; Seeger K; Mehta S; Fishman M; McGowan K; Strejcek K; Eiten E; Pirotte C; Lucier E; DeFrates S; Mehta J
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):584-589. PubMed ID: 28694084
[TBL] [Abstract][Full Text] [Related]
9. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Tan L; Liu J; Liu X; Chen J; Yan Z; Yang H; Zhang D
J Exp Clin Cancer Res; 2009 Sep; 28(1):131. PubMed ID: 19775450
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study).
Radhakrishnan V; Venkatakrishnan K; Perumal Kalaiyarasi J; Selvarajan G; Mahaboobasha N; Victor PV; Anbazhagan M; Sivanandam DM; Rajaraman S
JCO Glob Oncol; 2024 Jan; 10():e2300301. PubMed ID: 38237092
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
Wang SY; Yang ZJ; Zhang L
Asian Pac J Cancer Prev; 2014; 15(22):9587-92. PubMed ID: 25520071
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Navari RM; Qin R; Ruddy KJ; Liu H; Powell SF; Bajaj M; Dietrich L; Biggs D; Lafky JM; Loprinzi CL
N Engl J Med; 2016 Jul; 375(2):134-42. PubMed ID: 27410922
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it.
Ito S; Tsukiyama I; Ando M; Katakami M; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Asai N; Yokoe N; Takahashi A; Baba K; Matsuura K; Yamaguchi E; Kubo A
Support Care Cancer; 2015 Apr; 23(4):905-12. PubMed ID: 25223352
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India.
Babu G; Saldanha SC; Kuntegowdanahalli Chinnagiriyappa L; Jacob LA; Mallekavu SB; Dasappa L; Kiran PR; Sreevatsa A; Appachu S; Unnikrishnan V; Arroju V
Chemother Res Pract; 2016; 2016():3439707. PubMed ID: 26925265
[TBL] [Abstract][Full Text] [Related]
15. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.
Chanthawong S; Lim YH; Subongkot S; Chan A; Andalusia R; Ahmad Bustamam RS; Chaiyakunapruk N
Support Care Cancer; 2019 Mar; 27(3):1109-1119. PubMed ID: 30112718
[TBL] [Abstract][Full Text] [Related]
17. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study.
Shivaprakash G; Udupa KS; Sarayu V; Thomas J; Gupta V; Pallavi LC; Pemminati S
Indian J Pharmacol; 2017; 49(6):451-457. PubMed ID: 29674800
[TBL] [Abstract][Full Text] [Related]
19. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
20. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
Molassiotis A; Nguyen AM; Rittenberg CN; Makalinao A; Carides A
Future Oncol; 2013 Oct; 9(10):1443-50. PubMed ID: 23987791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
